A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques
- PMID: 20223370
- DOI: 10.1016/j.jacc.2009.11.051
A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques
Abstract
Objectives: The aim of this study was to understand the initial mechanism of arterial thrombus formation induced by vulnerable human atherosclerotic plaques to re-assess and improve current antithrombotic strategies.
Background: Rupture of atherosclerotic plaques causes arterial thrombus formation that might lead to myocardial infarction and ischemic stroke. Atherothrombosis is considered as an inseparable tangle of platelet activation and coagulation processes, involving plaque components such as tissue factor (TF) and collagen as well as blood-borne TF and coagulation factor XIIa (FXIIa). A combination of anticoagulants and antiplatelet agents is the present treatment.
Methods: Human atheromatous plaque material was exposed to blood or blood components at physiological calcium/magnesium concentration. Platelet aggregation and coagulation were measured under static and arterial flow conditions by state-of-the-art microscopic and physiological techniques. Plaque TF, plaque collagen, FXIIa, and platelet glycoprotein VI (GPVI) were specifically inhibited.
Results: Plaques induced thrombus formation by 2 discrete steps. The rapid first phase of GPVI-mediated platelet adhesion and aggregation onto plaque collagen occurred within 1 min. The second phase of coagulation started after a delay of >3 min with the formation of thrombin and fibrin, and was driven entirely by plaque TF. Coagulation occurred only in flow niches provided by platelet aggregates, with no evidence for a role of blood-borne TF and FXIIa. Inhibition of GPVI but not plaque TF inhibited plaque-induced thrombus formation.
Conclusions: The major thrombogenic plaque components--collagen and TF--induce platelet activation and coagulation, respectively, in 2 consecutive steps. Targeting specifically the first step is crucial and might be sufficient to inhibit atherothrombus formation.
Copyright 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI.FASEB J. 2005 Jun;19(8):898-909. doi: 10.1096/fj.04-2748com. FASEB J. 2005. PMID: 15923400
-
Dimeric Glycoprotein VI Binds to Collagen but Not to Fibrin.Thromb Haemost. 2018 Feb;118(2):351-361. doi: 10.1160/TH17-04-0302. Epub 2018 Jan 29. Thromb Haemost. 2018. PMID: 29378359
-
Differential Inhibition of Human Atherosclerotic Plaque-Induced Platelet Activation by Dimeric GPVI-Fc and Anti-GPVI Antibodies: Functional and Imaging Studies.J Am Coll Cardiol. 2015 Jun 9;65(22):2404-15. doi: 10.1016/j.jacc.2015.03.573. J Am Coll Cardiol. 2015. PMID: 26046734 Free PMC article.
-
Tissue factor and atherothrombosis.Curr Pharm Des. 2015;21(9):1152-7. doi: 10.2174/1381612820666141013154946. Curr Pharm Des. 2015. PMID: 25312727 Review.
-
Glycoprotein VI - novel target in antiplatelet medication.Pharmacol Ther. 2021 Jan;217:107630. doi: 10.1016/j.pharmthera.2020.107630. Epub 2020 Jul 16. Pharmacol Ther. 2021. PMID: 32681846 Review.
Cited by
-
The effect of factor VIII deficiencies and replacement and bypass therapies on thrombus formation under venous flow conditions in microfluidic and computational models.PLoS One. 2013 Nov 13;8(11):e78732. doi: 10.1371/journal.pone.0078732. eCollection 2013. PLoS One. 2013. PMID: 24236042 Free PMC article.
-
Integrating platelet and coagulation activation in fibrin clot formation.Res Pract Thromb Haemost. 2018 May 20;2(3):450-460. doi: 10.1002/rth2.12107. eCollection 2018 Jul. Res Pract Thromb Haemost. 2018. PMID: 30046749 Free PMC article. Review.
-
Low mean platelet volume is associated with critical limb ischemia in peripheral arterial occlusive disease.Sci Rep. 2018 Apr 30;8(1):6718. doi: 10.1038/s41598-018-25058-8. Sci Rep. 2018. PMID: 29713026 Free PMC article.
-
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.J Thromb Haemost. 2017 May;15(5):835-847. doi: 10.1111/jth.13651. Epub 2017 Mar 27. J Thromb Haemost. 2017. PMID: 28182323 Free PMC article. Review.
-
Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial.J Am Heart Assoc. 2020 Dec 15;9(24):e016495. doi: 10.1161/JAHA.120.016495. Epub 2020 Dec 11. J Am Heart Assoc. 2020. PMID: 33305660 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous